Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency.
Jørgensen SF, Macpherson ME, Bjørnetrø T, Holm K, Kummen M, Rashidi A, Michelsen AE, Lekva T, Halvorsen B, Trøseid M, Mollnes TE, Berge RK, Yndestad A, Ueland T, Karlsen TH, Aukrust P, Hov JR, Fevang B.
Jørgensen SF, et al. Among authors: bjornetro t.
Sci Rep. 2019 Jan 17;9(1):167. doi: 10.1038/s41598-018-35367-7.
Sci Rep. 2019.
PMID: 30655568
Free PMC article.
Retracted.
Clinical Trial.